Josh Richardson

Dr. Richardson is a Managing Director at Longitude Capital. Prior to Longitude Capital, Dr. Richardson was a Public Equities Analyst at HealthCor Management where he managed small and mid-cap biotechnology investments, and an Engagement Manager with McKinsey & Company. Dr. Richardson currently serves on the boards of Avenge Bio, Neurana Pharmaceuticals, Sublimity Therapeutics and Sierra Oncology (SRRA), and has been involved with a number of Longitude investments, including Aimmune Therapeutics (AIMT), Collegium Pharmaceuticals (COLL), Cadence Pharmaceuticals (CADX, acquired by Mallinckrodt), InfaCare Pharmaceutical (acquired by Mallinckrodt) and Precision Dermatology (acquired by Valeant Pharmaceuticals). He previously served on the boards of Epirium Bio and KaNDy Therapetuics (acquired by Bayer). Dr. Richardson also led Longitude Capital’s investment in Akebia Therapeutics (AKBA). Dr. Richardson holds an M.D. from the University of Virginia and a B.S. in biomedical science from the University of South Florida.